Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine and Endostar for Malignant Pleural Effusion in NSCLC
NCT02579564Phase 3Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Oct 2016
- Primary completion
- Jun 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 3, randomised, open-label trial of Oncorine and endostar in malignant pleural effusion (MPE) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Objective Response Rate of Malignant Pleural Effusions at 3 years. Status: unknown.
02
Drugs
Oncorineendostar
03
Conditions
malignant pleural effusion (MPE)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02579564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579564.